Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor

ConclusionsOnce-weekly trelagliptin 100  mg administered for 12 weeks resulted in a numerically, but not statistically, greater improvement in QOL and treatment satisfaction versus daily DPP-4 inhibitors. The decision to administer once-weekly or daily DPP-4 inhibitor treatment is likely to depend on patient preferences and the treatmen t policies of physicians.Trial RegistrationClinicalTrials.gov (NCT03014479) and JAPIC (JapicCTI-173482).FundingTakeda Pharmaceutical Company Ltd.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research